NCT02274766 - Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

March 10, 2016

Study Completion Date

March 10, 2016

Conditions

DyskinesiaLevodopa-Induced Dyskinesia (LID)Parkinson's Disease (PD)

Interventions

DRUG

ADS-5102

Oral capsules to be administered once nightly at bedtime, for 13 weeks.

OTHER

Placebo

Oral capsules to be administered once nightly at bedtime, for 13 weeks.

Trial Locations (51)

1080

Vienna

1220

Vienna

6020

Innsbruck

12163

Berlin

13353

Berlin

13385

Marseille

14547

Beelitz-Heilstätten

21075

Elkridge

21287

Baltimore

22291

Hamburg

24018

Roanoke

26506

Morgantown

27405

Greensboro

27607

Raleigh

30329

Atlanta

31059

Toulouse

32209

Jacksonville

33076

Bordeaux

33351

Sunrise

33486

Boca Raton

33612

Tampa

33980

Port Charlotte

34128

Kassel

34295

Montpellier

35033

Rennes

35043

Marburg

37075

Göttingen

48322

West Bloomfield

53233

Milwaukee

59037

Lille

60611

Chicago

63003

Clermont-Ferrand

66160

Kansas City

67098

Strasbourg

69677

Bron

74136

Tulsa

76031

Rouen

80804

München

81675

München

86021

Poitier

92708

Fountain Valley

94085

Sunnyvale

98034

Kirkland

02114

Boston

04103

Leipzig

07751

Gera

07646

Stadtroda

08028

Barcelona

08035

Barcelona

08036

Barcelona

08041

Barcelona